Retina

The FDA granted priority review of the biologics license application for NT-501 as a treatment for macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.

KIAWAH ISLAND, S.C. — A study suggested that electrocardiogram screening should be performed in patients with sarcoidosis-associated uveitis because life-threatening cardiac involvement may be present even without symptoms.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Michael Singer, MD, discusses a phase 2a study on ANXV in treatment-naive patients with retinal vein occlusion.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Anat Loewenstein, MD, of Tel Aviv Medical Center in Israel, discusses Axpaxli for the treatment of neovascular age-related macular degeneration.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Fred Guerard, CEO of Opthea, shares updates on the COAST and ShORe trials.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David A. Eichenbaum, MD, presents real-world data related to the use of aflibercept 8 mg.

In June, retina experts from around the world will convene in Park City, Utah, to discuss ongoing clinical trials, best trial practices and recent data at Clinical Trials at the Summit.

Wellness company HealthyCell has announced the launch of Eye Health, the newest supplement in the company’s MicroGel product line, which is designed to promote visual acuity, protect against oxidative stress and support retinal health.